Last reviewed · How we verify

NCT05373381

The KetoGlioma (Ketogenic Glioma) Study

Withdrawn NA Last updated 2 February 2024
What this trial tests

NA trial testing Supplemental High Fat Low Carbohydrate (sHFLC) + KetoPhyt in Glioma. Withdrawn.

Timeline
18 May 2022
Primary endpoint
18 May 2022
18 May 2022

Quick facts

Lead sponsorTufts Medical Center
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Start date18 May 2022
Primary completion18 May 2022
Estimated completion18 May 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Tufts Medical Center

Who can join

18 and older, any sex, with Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is being conducted to see if patients diagnosed with high grade gliomas can adhere to the supplemented High-Fat Low-Carbohydrate (sHFLC) + KetoPhyt diet, and to see how this diet might affect cancer cells in the bloodstream. This diet is experimental and is not routinely prescribed for patients with high-grade gliomas. The results of this study may be used to support larger studies investigating possible anti-tumor affects of the sHFLC + KetoPhyt diet.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Insight into the Functional Dynamics and Challenges of Exosomes in Pharmaceutical Innovation and Precision Medicine.
    Sharma A, Yadav A, Nandy A, Ghatak S. · · 2024 · cited 40× · PMID 38931833 · DOI 10.3390/pharmaceutics16060709
  2. The Role of Bacteria in Central Nervous System Tumors: Opportunities and Challenges.
    Zhang R, Li X, Zhang S. · · 2024 · cited 6× · PMID 38930435 · DOI 10.3390/microorganisms12061053
  3. Diet and Nutrients in Rare Neurological Disorders: Biological, Biochemical, and Pathophysiological Evidence.
    Briglia M, Allia F, Avola R, Signorini C, et al · · 2024 · cited 3× · PMID 39339713 · DOI 10.3390/nu16183114
  4. The advent of precision nutrigeroscience in cancer: from clinic towards molecular biology.
    Gao Z, Liu Y, Cui Y, Han Y, et al · · 2026 · cited 2× · PMID 40850675 · DOI 10.1016/j.jare.2025.08.034
  5. Exosomes in glioma: mechanistic insights on biological, therapeutic, and diagnostic perspective.
    Tandon R, Kumar S, Handa M, Srivastava N. · · 2025 · PMID 39957239 · DOI 10.1080/20415990.2025.2466410

Verify or expand the search:

Other recruiting trials for Glioma

Currently open trials in the same condition.

Other Tufts Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05373381.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing